SARS-COV-2 Vaccinations in RMD patients
The EULAR Task Force on COVID-19 has updated the EULAR View-points on SARS-CoV-2 vaccination in patients with RMDs (December 2021).
The information addresses questions, including considerations regarding vaccination effectiveness and safety, the third vaccination dose, booster vaccination, combination with Influenza and Pneumococcus vaccination, among other frequently asked questions by people with RMDs.
EULAR President, Prof Annamaria Iagnocco, invites you to share the link with your axSpA community.
Other NEWS
Staying Mentally Healthy in an Uncertain World
In our interconnected world, news of conflict and crisis—whether in …
Read More
Do Rheumatologists Know About the ASAS-EULAR Recommendations?
ASAS-EULAR want to know what rheumatologists know about the ASAS-EULAR …
Read More
Strengthening the Patient Voice in Global axSpA Research
The Assessment of SpondyloArthritis International Society (ASAS) Annual Meeting once …
Read More